"Insulin One Brother" status is not secure? A number of pharmaceutical companies snapped up the 25 billion market.

The 25 billion insulin market is climbing, with foreign drug companies accounting for 70% of the year, and the prevalence of diabetes has been rising, becoming a global problem.
According to the Diabetes Map (9th edition) released by the International Diabetes Alliance (IDF), there were 463 million people with diabetes worldwide in 2019, equivalent to 1 in 11 adults with diabetes, and 700 million people are expected to have diabetes by 2045.
notable is that china has 116 million people with diabetes, the number one in the world.
In recent years, china's public medical institutions terminal chemical drug insulin and its similar drugs sales (units: 10,000 yuan) for type 1 diabetes patients, insulin is the only treatment drug.
, 30-40% of people with type 2 diabetes end up using insulin. According to data from
, sales of insulin and similar drugs in the terminal chemicals of public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as public medical institutions) in China in 2019 were nearly 25 billion yuan, up 7.33 percent year-on-year.
in recent years, China's public medical institutions terminal chemical drug insulin and its similar drug channel pattern From the channel pattern, in recent years, urban public hospitals continued to decline, from 56.76 percent in 2015 to 43.58 percent in 2019, while urban community centers and township health centers have been growing steadily.
2019 China's urban public medical institutions terminal chemical drug insulin and its similar drug enterprise competition pattern From the competitive landscape of enterprises, Novo Nordisk, Sanofi and Lilly three foreign pharmaceutical companies have been in the top three positions, in 2019 the total market share of nearly 75%, Novo and Nordisk is the first.
in recent years, Novo Nordisk's sales growth has slowed, from 55.91 percent in 2015 to 47.41 percent in 2019, as domestic pharmaceutical companies such as Ganli Pharmaceuticals, Tonghua Dongbao Pharmaceuticals and Federal Pharmaceuticals have continued to grow.
7 over 1 billion brands bright eyes! Gan Li Pharmaceuticals, Tonghua Dongbao... Domestic pharmaceutical companies broke out of 2019 China's public medical institutions terminal chemical drug insulin and its similar drug brand TOP20 (units: 10,000 yuan) brand TOP10, Novo Nordisk, Sanofi, Lilly and other foreign pharmaceutical companies occupy 7 seats;
sales of more than 1 billion yuan, including Novo Nordisk's Mendon insulin 30 injections in the first place, sales of more than 5 billion yuan.
2 billion varieties hit the world, the domestic insulin leader listed in the day before, the domestic insulin leader Gan Li Pharmaceuticals by the Securities and Futures Commission issued an IPO approval, causing market concern, the purchase date on June 16, the issue price of 63.32 yuan (estimated), which means that the official landing of A shares has been close at hand.
data show that the company is mainly engaged in the reorganization of insulin analogue api and injection research and development, production and sales.
its main products include recombinant insulin glargine injection (commodity name: Changxiu), recombinant recombinant insulin injection (commodity name: quick show, refined protein zinc recombinant recombinant insulin-rejuvenate injection (25R).
2019, the company's revenue of 2.895 billion yuan, net profit of 1.167 billion yuan, of which, insulin preparation revenue accounted for up to 95.10%, recombinant insulin injection is the company's main source of revenue.
in recent years, China's public medical institutions insulin glargine sales (units: 10,000 yuan) minet data show that in recent years, China's public medical institutions terminal insulin glargine sales growth rate of more than 10%, in 2019 as high as 6,078 million yuan.
major producers are Sanofi, Ganli Pharmaceuticals and Federal Pharmaceuticals, among which, Ganli Pharmaceuticals' exclusive product recombinant insulin insulin injections are growing rapidly, with sales exceeding the 2 billion mark.
Gan Li Pharmaceuticals said that while maintaining high-end market growth, the company with the advantage of policy advantages, strong development of the grass-roots market, in the low-end market share further enhanced, covering the number of terminal hospitals increased more, the company's products in the domestic diabetes treatment drug clinical drug market share continues to increase.
Tonghua Dongbao focus on diabetes drugs, hybrid recombinant human insulin steady growth In recent years China's public medical institutions terminal hybrid recombinant human insulin sales (units: 10,000 yuan) mixed recombinant human insulin is tonghua Dongbao's exclusive products.
, china's public medical facilities in 2019 in the terminal hybrid recombinant human insulin sales of more than 1.8 billion yuan.
, including 30/70 mixed recombinant human insulin injection (commodity name: Ganshu-30R) and 50/50 mixed recombinant human insulin injection (commodity name: ganshua50R), while Ganshu-30R is the dominant product.
Tonghua Dongbao has been committed to focusing on the development of the treatment of diabetes in the field of products, to develop the field of diabetes treatment as the core, rich in the field of diabetes treatment product line.
December 2019, Tonghua Dongbao developed insulin glycol injections approved the market, becoming the third company in China to obtain the product registration approval.
Tonghua Dongbao said that the company, on the basis of the second generation of recombinant human insulin, actively carry out the research and development of three generations of insulin analogue (insulin glargine, mendong insulin, diedu insulin, repufusand insulin), as well as aniagocative sugar-lowering drugs, chemical oral sugar-lowering drugs, to meet the drug needs of different diabetic patients.
1 billion varieties to reach a new high! Federal pharmaceutical market share far ahead in recent years China's public medical institutions terminal sperm protein recombinant human insulin sales (units: 10,000 yuan) minet data show that in recent years, China's public medical institutions terminal refined protein recombinant human insulin sales grew rapidly, after breaking the 1 billion mark in 2018, 2019 year-on-year growth of 10.35 percent.
at present, the production enterprises have the Federal Pharmaceutical, Tonghua Dongbao Pharmaceuticals, BIOTON and Hefei Tianmai Bio 4, of which, the federal pharmaceutical market share of nearly 65%, Tonghua Dongbao accounted for 23.71%.
Federal Pharmaceuticals said in its 2019 annual report that the insulin line continued to fuel the growth of the company's preparation products business, with total sales revenue of $900 million, while sales of recombinant human insulin injections and insulin insulin injections increased by 12.7% and 158.5%, respectively, year-on-year.
future, the company will continue to use the insulin series as a strategic variety to drive its sales to continue to grow and increase market share.
Source: Minnet Database, Public Company Announcement Original Title: "Insulin One Brother" Status Is Not Guaranteed? Tonghua Dongbao, Gan Li Pharmaceuticals... Grab 25 billion market, seven over 1 billion brands bright eyes.